This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Axsome Expedites Completion Timeline of AD Study on AXS-05
by Zacks Equity Research
Axsome (AXSM) speeds up the evaluation time of AXS-05 under the phase II/III ADVANCE-1 study for Alzheimer's disease agitation to ensure safety of patients amid the COVID-19 pandemic.
Gilead's HCV Drug Epclusa Gets FDA Nod for Expanded Age Group
by Zacks Equity Research
The FDA approves Gilead's (GILD) sNDA for Epclusa to treat chronic hepatitis C infection in children aged six years and above or weighing at least 17 kg.
IMV to Develop Vaccine Candidate Against COVID-19, Shares Up
by Zacks Equity Research
IMV plans to develop a vaccine candidate using its lipid-based delivery platform, DPX technology, for the treatment of coronavirus disease. Stock rises.
These 10 Drug Companies are Testing a Coronavirus Vaccine
by Madeleine Johnson
As the coronavirus pandemic continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.
Inovio (INO) Stock Up YTD on Coronavirus Vaccine Efforts
by Zacks Equity Research
Inovio (INO) is developing INO-4800, its DNA vaccine to enter clinical testing soon, against COVID-19. The company's vaccine portfolio holds potential amid competition.
Coronavirus Vaccine Trial Begins, Biotech Competition Heats Up
by Kaibalya Pravo Dey
While the overall vaccine development process has been impressively fast so far, it might take 12-18 months to fully validate a potential vaccine.
Inovio (INO) Posts Wider Q4 Loss, Gets COVID-19 Vaccine Grant
by Zacks Equity Research
Inovio's (INO) loss in the fourth quarter falls shy of estimates and revenues too miss the mark. The company is focused on developing INO-4800, its DNA vaccine, against COVID-19.
Coronavirus Drug Development Efforts Pick Up Amid Sell-Off
by Kinjel Shah
Several drug/biotech companies are working on making new antibodies, drugs and vaccines to prevent and treat COVID-19.
Biotech Sector in Focus as Coronavirus Spreads Panic
by Ekta Bagri
The outbreak of COVID-19 has brought the volatile biotech sector under the spotlight as both large and small companies rush to develop treatments and vaccines to combat this pandemic.
Inovio Pharmaceuticals (INO) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Inovio (INO) delivered earnings and revenue surprises of -39.13% and -79.44%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Beat Virus With 2 Sector ETFs & Stocks That Survived 2008 Crisis
by Sanghamitra Saha
These two sectors lost lesser than the broader market during the 2008 financial crisis and may help you to tide over the latest virus crisis.
Emergent (EBS) Begins Development of Treatments for COVID-19
by Zacks Equity Research
Emergent (EBS) starts developing two plasma-derived product candidates for the treatment and prevention of coronavirus disease.
3 Small Biotechs Provide Coronavirus Drug Development Updates
by Kinjel Shah
Several drug/biotech companies are working on making new antibodies, drugs, and vaccines to prevent and treat COVID-19.
The Zacks Analyst Blog Highlights: Co-Diagnostics, GenMark Diagnostics, OPKO Health and Inovio Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Co-Diagnostics, GenMark Diagnostics, OPKO Health and Inovio Pharmaceuticals
4 Stocks to Gain the Most From the Coronavirus Outbreak
by Nilanjan Banerjee
It is worthwhile to keep an eye on stocks of companies that are engaged in the prevention, diagnosis and treatment of the disease.
The Zacks Analyst Blog Highlights: Moderna, Inovio Pharmaceuticals, Vir Biotechnology and Alnylam Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Inovio Pharmaceuticals, Vir Biotechnology and Alnylam Pharmaceuticals
Will Inovio Pharmaceuticals (INO) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Inovio (INO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
House Okays $8 Billion Funds to Combat COVID-19: 3 Winners
by Manaswita Ghosh Dutta
U.S. lawmakers' deal to find a vaccine for tackling the coronavirus stands to benefit the healthcare industry.
Inovio Surges on Expedited Timeline for Coronavirus Vaccine
by Zacks Equity Research
Inovio (INO) to initiate human clinical studies on INO-4800, its DNA vaccine, this April, for the treatment of the deadly coronavirus. The stock price shoots up.
5 Drug Makers to Gain From Coronavirus Outbreak
by Zacks Equity Research
Drug makers globally are working on developing therapies and vaccines for coronavirus. Here are five stocks that are currently in focus.
4 Top Stocks to Win Big From the Coronavirus Pandemic (Revised)
by Tirthankar Chakraborty
Professional money managers are looking to buy stocks that act as a hedge against coronavirus threat, or those that simply benefits from the particular event.
The Zacks Analyst Blog Highlights: Moderna, Inovio Pharmaceuticals, Co-Diagnostics and Apple
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Inovio Pharmaceuticals, Co-Diagnostics and Apple
5 Biotechs That Escaped the Coronavirus Onslaught Last Week
by Kinjel Shah
Here we discuss 5 biotech stocks that outperformed the industry amid the U.S. market slump.
4 Top Stocks to Win Big From the Coronavirus Pandemic
by Tirthankar Chakraborty
Professional money managers are looking to buy stocks that act as a hedge against coronavirus threat, or those that simply benefits from the particular event.
Inovio Pharmaceuticals (INO) Stock Moves -1.84%: What You Should Know
by Zacks Equity Research
In the latest trading session, Inovio Pharmaceuticals (INO) closed at $4.28, marking a -1.84% move from the previous day.